nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.10.2010 | Original Article

PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide ⁶⁸Ga-DOTAVAP-P1: comparison with ¹⁸F-FDG

verfasst von: Anu Autio, Tiina Ujula, Pauliina Luoto, Satu Salomäki, Sirpa Jalkanen, Anne Roivainen

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate inflammation and tumour imaging with a vascular adhesion protein 1 (VAP-1) targeting peptide ⁶⁸Ga-DOTAVAP-P1 in comparison with ¹⁸F-FDG.

Methods

Rats with both subcutaneous human pancreatic adenocarcinoma xenografts and turpentine oil-induced acute sterile inflammation were evaluated by dynamic positron emission tomography (PET) and by digital autoradiography of tissue cryosections. Subsequently, the autoradiographs were combined with histological and immunohistological analysis of the sections.

Results

⁶⁸Ga-DOTAVAP-P1 delineated acute, sterile inflammation comparable with ¹⁸F-FDG. However, the tumour uptake of ⁶⁸Ga-DOTAVAP-P1 was low in contrast to prominent ¹⁸F-FDG uptake. The standardised uptake values of inflammation and tumours by PET were 1.1 ± 0.4 (mean ± SEM) and 0.4 ± 0.1 for ⁶⁸Ga-DOTAVAP-P1 and 2.0 ± 0.5 and 1.6 ± 0.8 for ¹⁸F-FDG, respectively. In addition, PET studies showed inflammation to muscle and tumour to muscle ratios of 5.1 ± 3.1 and 1.7 ± 0.3 for ⁶⁸Ga-DOTAVAP-P1 and 6.2 ± 0.7 and 4.6 ± 2.2 for ¹⁸F-FDG, respectively. Immunohistochemistry revealed increased expression of luminal VAP-1 on the endothelium at the site of inflammation and low expression in the tumour

Conclusion

The ⁶⁸Ga-DOTAVAP-P1 PET was able to visualise inflammation better than tumour, which was in accordance with the luminal expression of VAP-1 on vasculature in these experimental models.

Smith DJ, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S. Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J Exp Med 1998;188:17–27.CrossRefPubMed

Salmi M, Jalkanen S. VAP-1: an adhesin and an enzyme. Trends Immunol 2001;22:211–6.CrossRefPubMed

Tohka S, Laukkanen M-L, Jalkanen S, Salmi M. Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates recruitment in vivo. FASEB J 2001;15:373–82.CrossRefPubMed

Jalkanen S, Salmi M. VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arterioscler Thromb Vasc Biol 2008;28:18–26.CrossRefPubMed

Yoong KF, McNab G, Hübscher SG, Adams DH. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol 1998;160:3978–88.PubMed

Irjala H, Salmi M, Alanen K, Grénman R, Jalkanen S. Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium. J Immunol 2001;166:6937–43.PubMed

Marttila-Ichihara F, Auvinen K, Elima K, Jalkanen S, Salmi M. Vascular adhesion protein-1 enhances tumor growth by supporting recruitment of Gr-1+CD11b+ myeloid cells into tumors. Cancer Res 2009;69:7875–83.CrossRefPubMed

Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Mazière B. FDG accumulation and tumor biology. Nucl Med Biol 1998;25:317–22.CrossRefPubMed

Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046–51.CrossRefPubMed

10.

Lankinen P, Mäkinen TJ, Pöyhönen TA, Virsu P, Salomäki S, Hakanen AJ, et al. (68)Ga-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones. Eur J Nucl Med Mol Imaging 2008;35:352–64.CrossRefPubMed

11.

Ujula T, Salomäki S, Virsu P, Lankinen P, Mäkinen TJ, Autio A, et al. Synthesis, 68Ga labeling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1: a potential PET imaging agent for diagnosing osteomyelitis. Nucl Med Biol 2009;36:631–41.CrossRefPubMed

12.

Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235–8.PubMed

13.

Mäkinen TJ, Lankinen P, Pöyhönen T, Jalava J, Aro HT, Roivainen A. Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus. Eur J Nucl Med Mol Imaging 2005;32:1259–68.CrossRefPubMed

14.

Ujula T, Salomäki S, Autio A, Luoto P, Tolvanen T, Lehikoinen P, et al. 68Ga-chloride PET reveals human pancreatic adenocarcinoma xenografts in rats—comparison with FDG. Mol Imaging Biol 2010;12:259–68. doi:10.1007/s11307-009-0267-3.CrossRefPubMed

15.

Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301–6.PubMed

16.

van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, de Vries EF, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004;45:695–700.PubMed

17.

Suzuki M, Yamaguchi K, Honda G, Iwata R, Furumoto S, Jeong MG, et al. An experimental study on O-[18F]fluoromethyl-L-tyrosine for differentiation between tumor and inflammatory tissues. Ann Nucl Med 2005;19:589–95.CrossRefPubMed

18.

Kubota K, Furumoto S, Iwata R, Fukuda H, Kawamura K, Ishiwata K. Comparison of 18F-fluoromethylcholine and 2-deoxy-D-glucose in the distribution of tumor and inflammation. Ann Nucl Med 2006;20:527–33.CrossRefPubMed

19.

Zhao S, Kuge Y, Kohanawa M, Takahashi T, Zhao Y, Yi M, et al. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT. J Nucl Med 2008;49:135–41.CrossRefPubMed

20.

Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, et al. Characterization of a new primary human pancreatic tumor line. Cancer Invest 1986;4:15–23.CrossRefPubMed

21.

Lalor PF, Edwards S, McNab G, Salmi M, Jalkanen S, Adams D. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol 2002;169:983–92.PubMed

22.

Farace P, D’Ambrosio D, Merigo F, Galiè M, Nanni C, Spinelli A, et al. Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target. Eur J Nucl Med Mol Imaging 2009;36:616–23.CrossRefPubMed

23.

Nakao A, Fujii T, Sugimoto H, Kanazumi N, Nomoto S, Kodera Y, et al. Oncological problems in pancreatic cancer surgery. World J Gastroenterol 2006;12:4466–72.PubMed

24.

Saif MW, Cornfeld D, Modarresifar H, Ojha B. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients. J Gastrointestin Liver Dis 2008;17:173–8.PubMed

25.

Nakata B, Nishimura S, Ishikawa T, Ohira M, Nishino H, Kawabe J, et al. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 2001;19:53–8.PubMed

26.

Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G, Pedrazzoli S. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 2003;7:953–9.CrossRefPubMed

27.

Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, et al. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2005;32:389–97.CrossRefPubMed

28.

van Kouwen MC, Jansen JB, van Goor H, de Castro S, Oyen WJ, Drenth JP. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging 2005;32:399–404.CrossRefPubMed

29.

Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 1979;3:299–308.CrossRefPubMed

30.

Visvikis D, Cheze-LeRest C, Costa DC, Bomanji J, Gacinovic S, Ell PJ. Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET. Eur J Nucl Med 2001;28:1326–35.CrossRefPubMed

31.

Boellaard R, van Lingen A, Lammertsma AA. Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J Nucl Med 2001;42:808–17.PubMed

Titel: PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG
verfasst von: Anu Autio
Tiina Ujula
Pauliina Luoto
Satu Salomäki
Sirpa Jalkanen
Anne Roivainen
Publikationsdatum: 01.10.2010
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1497-y

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2010

New SPECT technology: potential and challenges

Real-time breath-hold triggering of myocardial perfusion imaging with a novel cadmium-zinc-telluride detector gamma camera

Before and after treatment 18F-FDG PET/CT images in a patient with cutaneous T-cell lymphoma

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

EANM YIM 2010—Report

FDG-PET/CT in infections: the imaging method of choice?